MedlinevsThermo Fisher Scientific

MDLN and TMO stock compared: price, dividend, valuation and results, from SEC filings.

MDLN

Medline Inc.

$39.47

Value $32.0B

-1.28%
MDLN's page

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

Medline (MDLN) has a market value of $32.0B and Thermo Fisher Scientific (TMO) $260B. The P/E is 54.9 for MDLN and 36.8 for TMO. Dividend yield: MDLN none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MDLN$32.0B

    TMO$260B

    TMO is 8.1 times MDLN

  • Revenue, 12 months

    MDLN$30.7B

    TMO$47.4B

    TMO is 1.5 times MDLN

  • Net income, 12 months

    MDLN$582M

    TMO$7.1B

    TMO is 12 times MDLN

  • Operating margin

    MDLN5.7%

    TMO17.9%

    12.2 points apart

  • ROIC

    MDLN5.7%

    TMO8.2%

    2.5 points apart

  • P/E

    MDLN54.9

    TMO36.8

    MDLN is 1.5 times TMO

  • Dividend yield

    MDLN0.0%

    TMO0.3%

    0.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MDLN-3.7%

TMO+24.8%

801001202026

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MDLNMedlineTMOThermo Fisher Scientific

Valuation

MDLNTMO
Valuation
Price$39.47$700.22
Market value$32.0B$260B
Enterprise value (EV)$40.9B$295B
P/E54.936.8
P/E, 5-year median–32.7
P/B2.74.8
EV/EBIT23.534.9
Free cash flow yield5.9%2.9%

Results and growth

MDLNTMO
Results and growth
Revenue, 12 months$30.7B$47.4B
Net income, 12 months$582M$7.1B
Free cash flow, 12 months$1.9B$7.6B
Earnings per share, 12 months$0.72$18.96
Revenue growth, year on year11.5%3.9%
Revenue growth a year, past+10.6%over 2 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

MDLNTMO
Margins and returns on capital
Gross margin25.7%–
Operating margin5.7%17.9%
Net margin1.9%14.9%
ROIC5.7%8.2%
ROE5.4%13.4%

Balance sheet

MDLNTMO
Balance sheet
Cash$3.6B$6.1B
Total debt$12.6B$41.4B
Net debt / EBITDA3.33.7
Interest cover2.5×5.5×

Dividends and buybacks

MDLNTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield0.1%1.2%
Shareholder yield0.1%1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MDLN or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Medline or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 8.1 times Medline ($32.0B), at today's prices.

Which pays the higher dividend, MDLN or TMO?

The dividend yield at today's price is none for Medline and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

What is the P/E of MDLN and TMO?

At today's price, the P/E is 54.9 for MDLN and 36.8 for TMO. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Medline or Thermo Fisher Scientific?

Over the last twelve months, the net margin was 1.9% for Medline and 14.9% for Thermo Fisher Scientific, and the operating margin 5.7% and 17.9%. Revenue was $30.7B and $47.4B.

Which is the better investment, Medline or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.